Screener
Aclaris Therapeutics ACRS Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $19,167 | $19,960 |
| Short-term marketable securities | 72,389 | 70,791 |
| Accounts receivable, prepaid expenses and other current assets | 6,209 | 5,565 |
| Total current assets | 97,765 | 96,316 |
| Marketable securities | 79,065 | 60,612 |
| Property and equipment, net | 664 | 761 |
| Other assets | 2,199 | 2,771 |
| Total assets | $179,693 | $160,460 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's total current assets?
- Aclaris Therapeutics (ACRS) reported total current assets of $97.77M in Q2 2026.
- How has Aclaris Therapeutics's total current assets changed year-over-year?
- Aclaris Therapeutics's total current assets decreased by 6.2% year-over-year, from $104.2M to $97.77M.
- What is the long-term trend for Aclaris Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's total current assets has grown at a 10.9% compound annual growth rate (CAGR), from $57.49M to $96.32M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Aclaris Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude